TARS · Insider Trading

Tarsus Pharmaceuticals, Inc. Common Stock

Every open-market purchase and sale reported by TARS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.

Form 4 Filings
50
most recent
Open-Market Buys
0
code P
Sales
18
code S
Reporting Insiders
14
current holders
TARS — Recent Form 4 Transactions (latest 2026-11-17)
FiledInsiderRole TypeSharesValue
2026-11-17 Bobak R. Azamian President/CEO and Board Chair Sell −10,000 −$803.10K
2026-11-05 Neera Clase Chief Commercial Officer A +17,265 deriv. —
2026-09-17 Wendy L Yarno Director M +302 —
2026-09-17 David E I Pyott Director M +201 —
2026-09-17 William J Phd Link Director MIXED −12,299 −$979.74K
2026-09-09 Elizabeth Yeu Lin Chief Medical Officer Sell −13,953 −$1.22M
2026-09-09 Bobak R. Azamian President/CEO and Board Chair Sell −10,000 −$905.60K
2026-09-09 Seshadri Neervannan Chief Operating Officer Sell −4,564 −$387.94K
2026-09-03 Bobak R. Azamian President/CEO and Board Chair Sell −10,000 −$800.60K
2026-09-03 Elizabeth Yeu Lin Chief Medical Officer Sell −11,578 −$897.99K
2026-06-29 Bhaskar Chaudhuri Director A +6,254 deriv. —
2026-06-29 Scott W Morrison Director A +6,254 deriv. —
2026-06-29 David E I Pyott Director A +7,060 deriv. —
2026-06-29 Katherine Goodrich Director A +6,254 deriv. —
2026-06-29 Andrew D. Goldberg Director A +6,254 deriv. —
2026-06-29 William J Phd Link Director A +7,060 deriv. —
2026-06-29 Wendy L Yarno Director A +7,463 deriv. —
2026-06-22 Bobak R. Azamian President/CEO and Board Chair Sell −10,000 −$615.49K
2026-06-17 Jeffrey S Farrow See Remarks MIXED +13,485 −$877.44K
2026-06-17 William J Phd Link Director Sell −12,500 −$776.50K
2026-06-17 Katherine Goodrich Director Sell −2,954 −$183.38K
2026-06-16 Andrew D. Goldberg Director M +2,954 —
2026-06-16 Bhaskar Chaudhuri Director M +2,954 —
2026-06-16 Scott W Morrison Director M +2,954 —
2026-06-16 William J Phd Link Director M +2,954 —
2026-06-16 Wendy L Yarno Director M +2,954 —
2026-06-16 Katherine Goodrich Director M +2,954 —
2026-04-28 David E I Pyott Director M +1,383 —
2026-03-24 Seshadri Neervannan Chief Operating Officer Sell −2,989 −$199.52K
2026-03-19 Bryan Wahl General Counsel Sell −12,440 −$850.42K
2026-03-19 Seshadri Neervannan Chief Operating Officer Sell −11,324 −$772.44K
2026-03-19 Dianne C. Whitfield Chief Human Resources Officer Sell −12,274 −$839.07K
2026-03-19 Jeffrey S Farrow See Remarks Sell −6,430 −$439.57K
2026-03-19 Elizabeth Yeu Lin Chief Medical Officer Sell −1,144 −$78.20K
2026-03-19 Aziz Mottiwala Chief Commercial Officer Sell −13,056 −$892.53K
2026-03-19 Bobak R. Azamian President/CEO and Board Chair Sell −34,603 −$2.36M
2026-03-18 William J Phd Link Director Sell −12,500 −$859.82K
2026-03-17 Jeffrey S Farrow See Remarks M +13,042 —
2026-03-17 Bryan Wahl General Counsel M +24,236 —
2026-03-17 Dianne C. Whitfield Chief Human Resources Officer M +23,909 —
2026-03-17 Aziz Mottiwala Chief Commercial Officer M +26,482 —
2026-03-17 Elizabeth Yeu Lin Chief Medical Officer M +2,511 —
2026-03-17 Bobak R. Azamian President/CEO and Board Chair M +66,274 —
2026-03-17 Seshadri Neervannan Chief Operating Officer M +26,287 —
2026-03-09 Jeffrey S Farrow See Remarks A +50,030 deriv. —
2026-03-09 Elizabeth Yeu Lin Chief Medical Officer A +44,471 deriv. —
2026-03-09 Bobak R. Azamian President/CEO and Board Chair A +157,499 deriv. —
2026-03-09 Bryan Wahl General Counsel A +44,471 deriv. —
2026-03-09 Seshadri Neervannan Chief Operating Officer A +44,471 deriv. —
2026-03-09 Dianne C. Whitfield Chief Human Resources Officer A +44,471 deriv. —
TARS — Current Insider Holders
InsiderRole Shares HeldValue
Bobak R. Azamian President/CEO and Board Chair 851,412 $66.32M
William J Phd Link Director 94,487 $7.36M
Seshadri Neervannan Chief Operating Officer 79,007 $6.15M
Bryan Wahl General Counsel 63,959 $4.98M
Aziz Mottiwala Chief Commercial Officer 61,480 $4.79M
Jeffrey S Farrow See Remarks 56,801 $4.42M
Dianne C. Whitfield Chief Human Resources Officer 35,028 $2.73M
Andrew D. Goldberg Director 19,654 $1.53M
Wendy L Yarno Director 16,956 $1.32M
Elizabeth Yeu Lin Chief Medical Officer 16,177 $1.26M
Scott W Morrison Director 13,654 $1.06M
Bhaskar Chaudhuri Director 11,654 $907.73K
David E I Pyott Director 10,958 $853.52K
Katherine Goodrich Director 2,233 $173.93K
TARS Insider Trading FAQ
Who are the insiders at TARS?
14 officers, directors and 10%+ beneficial owners currently report holdings in TARS via SEC Form 4.
Are TARS insiders buying or selling?
Across the 50 most recent Form 4 filings for TARS, 0 were open-market purchases (code P) and 18 were sales (code S). Sales frequently reflect scheduled 10b5-1 plans or tax withholding rather than a view on the stock.
How current is TARS insider data?
Form 4 must be filed within two business days of the transaction, so this is close to real time. The most recent TARS filing is dated 2026-11-17.
How to read Form 4 activity

Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.

Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.

Full filing history and per-insider positions are on the TARS quote page; the site-wide leaderboard is on the insider transactions hub.

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.